EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70500 ↗Kurz gefasst
Leserbrief in der Zeitschrift HemaSphere, online erschienen am 15.10.2026. Verfasst von Carolina Martínez-Laperche und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department Hospital General Universitario Gregorio Marañón Madrid Spain. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Hematology Department Hospital General Universitario Gregorio Marañón Madrid Spain.
- Instituto de Investigación Sanitaria Gregorio Marañón Madrid Spain.
- Hematology Department Hospital Universitario Son Espases, IdISBA Palma de Mallorca Spain.
- Department of Hematology Hospital del Mar Medical Research Institute Barcelona Spain.
- Hematology Department Hospital Universitario Ramón y Cajal Madrid Spain.
- Hematology Department Hospital Clínico Universitario de Valencia Valencia Spain.
ORCID-Profile: Carolina Martínez-Laperche, Pilar Lancho-Lavilla, Antonio Gutiérrez, Blanca Ferrer-Lores, Alicia Serrano, Francisco Javier Díaz-Crespo, Ismael Buño, Paula Muñiz, Pablo Silva-de-Tena, Ramón García-Sanz, Miguel Alcoceba
Zitieren
APA
Martínez-Laperche, C., Lancho-Lavilla, P., Gutiérrez, A., Salar, A., López-Jiménez, J., Ferrer-Lores, B., Serrano, A., Jiménez-Ubieto, A., Poza, M., Díaz-Crespo, F. J., Fernández-Caldas, P., Sanz-Villanueva, L., Menárguez-Palanca, J., Buño, I., García-Álvarez, M., Muñiz, P., Silva-de-Tena, P., García-Sanz, R., Alcoceba, M., & Bastos-Oreiro, M. (2026). EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70500
Vancouver
Martínez-Laperche C, Lancho-Lavilla P, Gutiérrez A, Salar A, López-Jiménez J, Ferrer-Lores B, et al. EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study. HemaSphere. 2026;10(10). doi:10.1002/hem3.70500
BibTeX
@article{MartnezLaperche2026,
author = {Martínez-Laperche, Carolina and Lancho-Lavilla, Pilar and Gutiérrez, Antonio and Salar, Antonio and López-Jiménez, Javier and Ferrer-Lores, Blanca and Serrano, Alicia and Jiménez-Ubieto, Ana and Poza, María and Díaz-Crespo, Francisco Javier and Fernández-Caldas, Paula and Sanz-Villanueva, Laura and Menárguez-Palanca, Javier and Buño, Ismael and García-Álvarez, María and Muñiz, Paula and Silva-de-Tena, Pablo and García-Sanz, Ramón and Alcoceba, Miguel and Bastos-Oreiro, Mariana},
title = {EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70500}
}
EUVIMED